Bonnie L. Blazer-Yost
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Bonnie L. Blazer-Yost has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
Alexandra Hochstetler
Harvard Medical School
5 shared publications- Gowthami Mahendran
Hydrocephalus Research Center, Department of Biology, Indiana University, Indianapolis, IN, USA
4 shared publications David Audu
Hydrocephalus Research Center, Department of Biology, Indiana University, Indianapolis, IN, USA
3 shared publicationsLouise Hulme
Department of Biology, SL358, Indiana University Purdue University Indianapolis, Indianapolis, USA
3 shared publications- Christian Schwerk
Pediatric Infectious Diseases, Department of Pediatrics, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
2 shared publications Horst Schroten
Department of Pediatrics, Pediatric Infectious Diseases, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
2 shared publications
Latest Publications
- 19 November 2026
- Published by American Physiological Society in American Journal of Physiology-Cell Physiology
Relationship between TRPV4, NKCC1 and lysophosphatidic acid in fluid and electrolyte secretion in a pre-clinical model of the human choroid plexus epithelium
Determination of factors responsible for producing cerebrospinal fluid (CSF) in physiological and pathophysiological conditions is important for identifying drug targets for disease states, notably hydrocephalus. We have previously identified the transient receptor potential vanilloid 4 (TRPV4) as an ion channel involved in CSF production by the choroid plexus epithelial cells in vitro and in vivo in a rat model of hydrocephalus. Another transporter that has been shown to be important for CSF production is the sodium, potassium, 2 chloride transporter, NKCC1. In addition, bioactive lipids such as lysophosphatidic acid (LPA) have been reported to cause choroid plexus-mediated hypersecretion of CSF. A recent report has linked these three important effectors and proposed that LPA drives CSF secretion via TRPV4-induced hyperactivation of NKCC1 (1). We used a well-characterized human choroid plexus epithelial cell line to examine these relationships in a cell type where all the relevant channels and proteins are expressed endogenously. We found a role for a complex signaling cascade involving TRPV4 and NKCC1. We could not replicate the finding that LPA stimulates TRPV4. Despite the endogenous expression of LPA receptors, LPA does not modulate fluid secretion in the choroid plexus cell line, nor does it participate in a potential TRPV4-NKCC1 signaling axis. In summary, we agree that components of the proposed TRPV4-NKCC1 pathway may be implicated in CSF production and in conditions such as hydrocephalus, but the role of LPA was not substantiated by our studies.
- 19 November 2026
- Published by American Physiological Society in American Journal of Physiology-Cell Physiology
Relationship between TRPV4, NKCC1 and lysophosphatidic acid in fluid and electrolyte secretion in a pre-clinical model of the human choroid plexus epithelium
Determination of factors responsible for producing cerebrospinal fluid (CSF) in physiological and pathophysiological conditions is important for identifying drug targets for disease states, notably hydrocephalus. We have previously identified the transient receptor potential vanilloid 4 (TRPV4) as an ion channel involved in CSF production by the choroid plexus epithelial cells in vitro and in vivo in a rat model of hydrocephalus. Another transporter that has been shown to be important for CSF production is the sodium, potassium, 2 chloride transporter, NKCC1. In addition, bioactive lipids such as lysophosphatidic acid (LPA) have been reported to cause choroid plexus-mediated hypersecretion of CSF. A recent report has linked these three important effectors and proposed that LPA drives CSF secretion via TRPV4-induced hyperactivation of NKCC1 (1). We used a well-characterized human choroid plexus epithelial cell line to examine these relationships in a cell type where all the relevant channels and proteins are expressed endogenously. We found a role for a complex signaling cascade involving TRPV4 and NKCC1. We could not replicate the finding that LPA stimulates TRPV4. Despite the endogenous expression of LPA receptors, LPA does not modulate fluid secretion in the choroid plexus cell line, nor does it participate in a potential TRPV4-NKCC1 signaling axis. In summary, we agree that components of the proposed TRPV4-NKCC1 pathway may be implicated in CSF production and in conditions such as hydrocephalus, but the role of LPA was not substantiated by our studies.
- Open Access
Therapeutic Potential of Melatonin, Erythropoietin, and TRPV4 Antagonism in a Preclinical Model of Genetic Hydrocephalus
Symptomatic hydrocephalus is a neuropathological disorder of cerebrospinal fluid (CSF) homeostasis characterized by abnormal accumulation of CSF and progressive ventricular enlargement. Current treatment relies primarily on surgical CSF diversion, which is invasive and associated with substantial rates of treatment failure and surgical revisions. Congenital hydrocephalus can be caused by genetic pathologies; for example, a point mutation in the Meckel-Gruber type 3, Tmem 67, gene produces a congenital hydrocephalus phenotype in rats, characterized by progressive ventriculomegaly. Here, we evaluated a combinatorial cocktail therapeutic strategy consisting of erythropoietin (EPO), melatonin (MLT), and the transient receptor potential vanilloid 4 (TRPV4) antagonist, RN1734 (RN), in the Tmem 67□□□ rat model of congenital hydrocephalus. Magnetic Resonance Imaging (MRI) demonstrated marked progression of ventriculomegaly in untreated Tmem 67□□□ rats between postnatal (P) 7 and P15. RN1734 and EPO+MLT+RN1734 (triple therapy) from P7-P14 prevented further ventricular expansion. Hydrocephalus is associated with structural disruption of the periventricular white matter (WM) and ependymal lining (EL), accompanied by regionally increased TLR4 and NLRP3-associated inflammatory signaling. EPO+MLT, RN1734, or triple therapy differentially attenuated these inflammatory responses. The triple combination reduced both TLR4 and NLRP3 protein abundance within the affected periventricular region and ameliorated the structural alterations. These findings support a combined therapeutic approach that addresses ventricular pathology, inflammation and periventricular structural consequences of congenital hydrocephalus.
Open AccessTherapeutic Potential of Melatonin, Erythropoietin, and TRPV4 Antagonism in a Preclinical Model of Genetic Hydrocephalus
Symptomatic hydrocephalus is a neuropathological disorder of cerebrospinal fluid (CSF) homeostasis characterized by abnormal accumulation of CSF and progressive ventricular enlargement. Current treatment relies primarily on surgical CSF diversion, which is invasive and associated with substantial rates of treatment failure and surgical revisions. Congenital hydrocephalus can be caused by genetic pathologies; for example, a point mutation in the Meckel-Gruber type 3, Tmem 67, gene produces a congenital hydrocephalus phenotype in rats, characterized by progressive ventriculomegaly. Here, we evaluated a combinatorial cocktail therapeutic strategy consisting of erythropoietin (EPO), melatonin (MLT), and the transient receptor potential vanilloid 4 (TRPV4) antagonist, RN1734 (RN), in the Tmem 67□□□ rat model of congenital hydrocephalus. Magnetic Resonance Imaging (MRI) demonstrated marked progression of ventriculomegaly in untreated Tmem 67□□□ rats between postnatal (P) 7 and P15. RN1734 and EPO+MLT+RN1734 (triple therapy) from P7-P14 prevented further ventricular expansion. Hydrocephalus is associated with structural disruption of the periventricular white matter (WM) and ependymal lining (EL), accompanied by regionally increased TLR4 and NLRP3-associated inflammatory signaling. EPO+MLT, RN1734, or triple therapy differentially attenuated these inflammatory responses. The triple combination reduced both TLR4 and NLRP3 protein abundance within the affected periventricular region and ameliorated the structural alterations. These findings support a combined therapeutic approach that addresses ventricular pathology, inflammation and periventricular structural consequences of congenital hydrocephalus.
- Open Access
Use of Integrative Proteomic Analysis to Uncover Shared Molecular Signatures Across Distinct Forms of Hydrocephalus
Hydrocephalus is a heterogeneous disease characterized by disruption of cerebrospinal fluid (CSF) dynamics and can arise from diverse etiologies, including post-hemorrhagic hydrocephalus (PHH), hydrocephalus following subarachnoid hemorrhage (SAH), post-infectious hydrocephalus (PIH), and idiopathic normal pressure hydrocephalus (iNPH). Hydrocephalus has high disease burden in pediatric and older populations and a marked increase in prevalence with advancing age. Despite this high incidence, the underpinning molecular and signaling pathway alterations remain incompletely understood. Hence CSF proteomic profiling would enable a robust and high-resolution approach for exploring disease-specific biomarkers and to discover shared molecular mechanisms underlying hydrocephalus. In this study, we performed a cross-study proteomic analysis to evaluate biomarker proteins reported across PHH, SAH, PIH, and iNPH groups. Using published proteomic datasets, we comparatively analyzed CSF proteins to investigate the differentially expressed proteins (DEPs), their common molecular signatures, and enriched biological pathways across hydrocephalus groups. Across etiologies, recurrently altered proteins were predominantly associated with inflammatory signaling (cytokine, chemokine, interleukin-(IL-17), tumor necrosis factor (TNF)), toll-like receptor (TLR) signaling, blood-brain-barrier (BBB) disruption leading to coagulation cascades, and neuronal injury responses. Hemorrhage-associated forms of hydrocephalus (PHH and SAH) demonstrated enriched coagulation and hemoglobin-related pathways, whereas infection associated forms (PIH) showed enhanced immune and inflammatory responses. iNPH exhibited alterations in proteins linked to neurodegeneration, synaptic function, and impaired CSF clearance. Interestingly, our cross-study analyses identified recurrently dysregulated proteins across hydrocephalus subtypes. Collectively, our cross-study proteomic analyses define shared and etiology-specific proteomic signatures across hydrocephalus subtypes and identify potential CSF-based biomarkers for diagnostic stratification and future precision therapeutic approaches.
Open AccessUse of Integrative Proteomic Analysis to Uncover Shared Molecular Signatures Across Distinct Forms of Hydrocephalus
Hydrocephalus is a heterogeneous disease characterized by disruption of cerebrospinal fluid (CSF) dynamics and can arise from diverse etiologies, including post-hemorrhagic hydrocephalus (PHH), hydrocephalus following subarachnoid hemorrhage (SAH), post-infectious hydrocephalus (PIH), and idiopathic normal pressure hydrocephalus (iNPH). Hydrocephalus has high disease burden in pediatric and older populations and a marked increase in prevalence with advancing age. Despite this high incidence, the underpinning molecular and signaling pathway alterations remain incompletely understood. Hence CSF proteomic profiling would enable a robust and high-resolution approach for exploring disease-specific biomarkers and to discover shared molecular mechanisms underlying hydrocephalus. In this study, we performed a cross-study proteomic analysis to evaluate biomarker proteins reported across PHH, SAH, PIH, and iNPH groups. Using published proteomic datasets, we comparatively analyzed CSF proteins to investigate the differentially expressed proteins (DEPs), their common molecular signatures, and enriched biological pathways across hydrocephalus groups. Across etiologies, recurrently altered proteins were predominantly associated with inflammatory signaling (cytokine, chemokine, interleukin-(IL-17), tumor necrosis factor (TNF)), toll-like receptor (TLR) signaling, blood-brain-barrier (BBB) disruption leading to coagulation cascades, and neuronal injury responses. Hemorrhage-associated forms of hydrocephalus (PHH and SAH) demonstrated enriched coagulation and hemoglobin-related pathways, whereas infection associated forms (PIH) showed enhanced immune and inflammatory responses. iNPH exhibited alterations in proteins linked to neurodegeneration, synaptic function, and impaired CSF clearance. Interestingly, our cross-study analyses identified recurrently dysregulated proteins across hydrocephalus subtypes. Collectively, our cross-study proteomic analyses define shared and etiology-specific proteomic signatures across hydrocephalus subtypes and identify potential CSF-based biomarkers for diagnostic stratification and future precision therapeutic approaches.
- Open Access
TRPV4 antagonist efficacy in a post-hemorrhagic hydrocephalus pig model
Summary: Hydrocephalus occurs across the age spectrum but is particularly prevalent in young and old individuals. One form of this disease is post-hemorrhagic hydrocephalus (PHH), which is a life-threatening sequela of intraventricular hemorrhage (IVH). There are no effective non-surgical interventions for the treatment of PHH or other forms of hydrocephalus. Progress has been limited by the lack of gyrencephalic animal models that exhibit high fidelity to human conditions. Here, we establish a pathophysiologically relevant novel swine model of IVH that recapitulates key features of severe PHH, including sustained ventriculomegaly, elevated intracranial pressure (ICP), neuroinflammation and white matter injury. Using this model, we test the therapeutic potential of pharmacologic inhibition of the transient receptor potential vanilloid 4 (TRPV4) non-specific cationic channel. The orally bioavailable TRPV4 antagonist GSK2789917 penetrates the blood-brain barrier, and prevents progression to PHH when administered 2 days after IVH. Specifically, GSK2789917 prevents the development of ventriculomegaly, suppresses early ICP elevations and prevents or reverses inflammasome activation. These findings establish a clinically relevant large-animal model of PHH and identify TRPV4 antagonism as a promising treatment for hydrocephalus.
Open AccessTRPV4 antagonist efficacy in a post-hemorrhagic hydrocephalus pig model
Summary: Hydrocephalus occurs across the age spectrum but is particularly prevalent in young and old individuals. One form of this disease is post-hemorrhagic hydrocephalus (PHH), which is a life-threatening sequela of intraventricular hemorrhage (IVH). There are no effective non-surgical interventions for the treatment of PHH or other forms of hydrocephalus. Progress has been limited by the lack of gyrencephalic animal models that exhibit high fidelity to human conditions. Here, we establish a pathophysiologically relevant novel swine model of IVH that recapitulates key features of severe PHH, including sustained ventriculomegaly, elevated intracranial pressure (ICP), neuroinflammation and white matter injury. Using this model, we test the therapeutic potential of pharmacologic inhibition of the transient receptor potential vanilloid 4 (TRPV4) non-specific cationic channel. The orally bioavailable TRPV4 antagonist GSK2789917 penetrates the blood-brain barrier, and prevents progression to PHH when administered 2 days after IVH. Specifically, GSK2789917 prevents the development of ventriculomegaly, suppresses early ICP elevations and prevents or reverses inflammasome activation. These findings establish a clinically relevant large-animal model of PHH and identify TRPV4 antagonism as a promising treatment for hydrocephalus.
- Open Access
- 18 September 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (18) , 8305
Phosphoproteomic Insights into TRPV4–AMPK Signaling Axis and Barrier Regulation in the Choroid Plexus Epithelium
Hydrocephalus is characterized by the abnormal accumulation of cerebrospinal fluid (CSF) due to disrupted secretion, circulation, or reabsorption. CSF homeostasis is regulated by ion and water channels on choroid plexus epithelial (CPe) cells, including the mechanosensitive cation channel, which is transient receptor potential vanilloid 4 (TRPV4). Although TRPV4 antagonism prevents hydrocephalus progression in rats, how TRPV4 activity modulates CSF production remains unclear. Because TRPV4 function is phosphorylation-dependent, we examined its activation (GSK1016790A) and inhibition (RN1734) and the downstream signaling alterations in the human choroid plexus papilloma cell line (HIBCPP) using phosphoproteomic mass spectrometry. Our phosphoproteomic analysis revealed significant changes in kinases and tight junction (TJ) proteins regulating epithelial barrier integrity. TRPV4 activation altered the phosphorylation of TJ proteins, including Zonula Occludens-1 (ZO-1) and Claudin-7 (CLDN7), as well as AMP-activated protein kinase (AMPK), with a notable increase in the phosphorylation of the AMPK inhibitory site (Ser496). Using electrophysiological techniques, we showed that AMPK had a more profound effect on epithelial barrier function than on net transepithelial electrolyte ion flux. The inhibition of AMPK-associated inhibitory phosphorylation prior to TRPV4 activation increased barrier tightness, and these permeability changes were mirrored by changes in ZO-1 continuity within junctional complexes. Furthermore, the pharmacological modulation of AMPK-associated signaling altered TRPV4-stimulated epithelial conductance, while metformin treatment also reduced TRPV4-stimulated conductance under the experimental conditions used. These findings suggest an interaction between TRPV4 signaling, AMPK phosphorylation, and epithelial barrier regulation that warrants further mechanistic investigation. Overall, these findings provide insight into signaling pathways associated with the TRPV4-dependent regulation of choroid plexus epithelial barrier properties and provide a basis for the further investigation of their relevance to CSF homeostasis and hydrocephalus.
- 18 September 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (18) , 8305
Open AccessPhosphoproteomic Insights into TRPV4–AMPK Signaling Axis and Barrier Regulation in the Choroid Plexus Epithelium
Hydrocephalus is characterized by the abnormal accumulation of cerebrospinal fluid (CSF) due to disrupted secretion, circulation, or reabsorption. CSF homeostasis is regulated by ion and water channels on choroid plexus epithelial (CPe) cells, including the mechanosensitive cation channel, which is transient receptor potential vanilloid 4 (TRPV4). Although TRPV4 antagonism prevents hydrocephalus progression in rats, how TRPV4 activity modulates CSF production remains unclear. Because TRPV4 function is phosphorylation-dependent, we examined its activation (GSK1016790A) and inhibition (RN1734) and the downstream signaling alterations in the human choroid plexus papilloma cell line (HIBCPP) using phosphoproteomic mass spectrometry. Our phosphoproteomic analysis revealed significant changes in kinases and tight junction (TJ) proteins regulating epithelial barrier integrity. TRPV4 activation altered the phosphorylation of TJ proteins, including Zonula Occludens-1 (ZO-1) and Claudin-7 (CLDN7), as well as AMP-activated protein kinase (AMPK), with a notable increase in the phosphorylation of the AMPK inhibitory site (Ser496). Using electrophysiological techniques, we showed that AMPK had a more profound effect on epithelial barrier function than on net transepithelial electrolyte ion flux. The inhibition of AMPK-associated inhibitory phosphorylation prior to TRPV4 activation increased barrier tightness, and these permeability changes were mirrored by changes in ZO-1 continuity within junctional complexes. Furthermore, the pharmacological modulation of AMPK-associated signaling altered TRPV4-stimulated epithelial conductance, while metformin treatment also reduced TRPV4-stimulated conductance under the experimental conditions used. These findings suggest an interaction between TRPV4 signaling, AMPK phosphorylation, and epithelial barrier regulation that warrants further mechanistic investigation. Overall, these findings provide insight into signaling pathways associated with the TRPV4-dependent regulation of choroid plexus epithelial barrier properties and provide a basis for the further investigation of their relevance to CSF homeostasis and hydrocephalus.
- Open Access
Phosphoproteomic Insights into TRPV4–AMPK Signaling Axis in the Choroid Plexus Epithelium: Implications for Therapeutic Targeting in Hydrocephalus
Background: Hydrocephalus is characterized by abnormal accumulation of cerebrospinal fluid (CSF) due to disrupted secretion, circulation, or reabsorption. CSF homeostasis is regulated by ion and water channels on choroid plexus epithelial (CPe) cells, including the mechanosensitive cation channel, transient receptor potential vanilloid 4 (TRPV4). Although TRPV4 antagonism prevents hydrocephalus progression in rats, how TRPV4 activity modulates CSF production remains unclear. Methods: Because TRPV4 function is phosphorylation-dependent, we examined its activation (GSK1016790A) and inhibition (RN1734) and the downstream signaling alterations in human choroid plexus papilloma cells (HIBCPP) using phosphoproteomic mass spectrometry. Results: Our phosphoproteomic analysis revealed significant changes in kinases and tight junction (TJ) proteins regulating epithelial barrier integrity. TRPV4 activation altered TJ proteins such as Zonula Occludens-1 (ZO-1), and Claudin-7 (CLDN7) and AMP-activated protein kinase (AMPK), phosphorylation, with a notable foldchange increase of AMPK inhibitory phospho form (Ser496). Further our electrophysiological and biochemical analyses demonstrated that AMPK activation followed by TRPV4 stimulation increased AMPK Ser496 phosphorylation, and epithelial permeability was subsequently elevated, although it was statistically not significant. In contrast, AMPK inhibition prior to TRPV4 activation resulted in the opposite effect with substantial epithelial barrier tightness which was evident from the ZO-1 expression. Moreover, a pharmacologically available anti-diabetic drug, metformin exhibited a similar trend like Compound C in reducing the barrier epithelial permeability after TRPV4 agonist treatment, highlighting that metformin promotes barrier tightness via an AMPK-dependent pathway coupled to TRPV4 signaling. Conclusions: Overall, these findings identify an AMPK–TRPV4 signaling axis that modulates epithelial permeability and may influence CSF regulation, highlighting a potential therapeutic target for hydrocephalus.
Open AccessPhosphoproteomic Insights into TRPV4–AMPK Signaling Axis in the Choroid Plexus Epithelium: Implications for Therapeutic Targeting in Hydrocephalus
Background: Hydrocephalus is characterized by abnormal accumulation of cerebrospinal fluid (CSF) due to disrupted secretion, circulation, or reabsorption. CSF homeostasis is regulated by ion and water channels on choroid plexus epithelial (CPe) cells, including the mechanosensitive cation channel, transient receptor potential vanilloid 4 (TRPV4). Although TRPV4 antagonism prevents hydrocephalus progression in rats, how TRPV4 activity modulates CSF production remains unclear. Methods: Because TRPV4 function is phosphorylation-dependent, we examined its activation (GSK1016790A) and inhibition (RN1734) and the downstream signaling alterations in human choroid plexus papilloma cells (HIBCPP) using phosphoproteomic mass spectrometry. Results: Our phosphoproteomic analysis revealed significant changes in kinases and tight junction (TJ) proteins regulating epithelial barrier integrity. TRPV4 activation altered TJ proteins such as Zonula Occludens-1 (ZO-1), and Claudin-7 (CLDN7) and AMP-activated protein kinase (AMPK), phosphorylation, with a notable foldchange increase of AMPK inhibitory phospho form (Ser496). Further our electrophysiological and biochemical analyses demonstrated that AMPK activation followed by TRPV4 stimulation increased AMPK Ser496 phosphorylation, and epithelial permeability was subsequently elevated, although it was statistically not significant. In contrast, AMPK inhibition prior to TRPV4 activation resulted in the opposite effect with substantial epithelial barrier tightness which was evident from the ZO-1 expression. Moreover, a pharmacologically available anti-diabetic drug, metformin exhibited a similar trend like Compound C in reducing the barrier epithelial permeability after TRPV4 agonist treatment, highlighting that metformin promotes barrier tightness via an AMPK-dependent pathway coupled to TRPV4 signaling. Conclusions: Overall, these findings identify an AMPK–TRPV4 signaling axis that modulates epithelial permeability and may influence CSF regulation, highlighting a potential therapeutic target for hydrocephalus.
- 16 July 2025
- Published by American Physiological Society in American Journal of Physiology-Cell Physiology
Hugh Davson: The Scientist and His Science
Each year the American Physiological Society and its various sections award named lectureships which honor the legacy of physiologists who have been instrumental in establishing important and enduring scientific principles. However, as the decades pass and many layers are added to the founding principles, the original science of these important luminaries begins to dim as we forget how important the original discoveries were to our current endeavors. In that context we would like to highlight some of the important contributions of Hugh Davson (1909-1996). One of us (JGM) considers Dr. Davson a significant mentor; the other of us (BBY) is honored to be awarded the 2025 Davson lectureship of the Cell and Molecular Physiology Section. In this historical perspective the authors wish to review the legacy of Hugh Davson from the perspective of both the scientist and his science. When pressed to acknowledge the scientific contributions of Hugh Davson, most physiologists, particularly those of a certain age, will cite the Davson-Danielli model of the plasma membrane. However, the current authors would like to acknowledge Dr. Davson‘s enduring contributions in another area, that of his fundamental studies of the ocular and cerebrospinal fluids that form the basis of our current research in this important aspect of fluid electrolyte homeostasis in the brain.
- 16 July 2025
- Published by American Physiological Society in American Journal of Physiology-Cell Physiology
Hugh Davson: The Scientist and His Science
Each year the American Physiological Society and its various sections award named lectureships which honor the legacy of physiologists who have been instrumental in establishing important and enduring scientific principles. However, as the decades pass and many layers are added to the founding principles, the original science of these important luminaries begins to dim as we forget how important the original discoveries were to our current endeavors. In that context we would like to highlight some of the important contributions of Hugh Davson (1909-1996). One of us (JGM) considers Dr. Davson a significant mentor; the other of us (BBY) is honored to be awarded the 2025 Davson lectureship of the Cell and Molecular Physiology Section. In this historical perspective the authors wish to review the legacy of Hugh Davson from the perspective of both the scientist and his science. When pressed to acknowledge the scientific contributions of Hugh Davson, most physiologists, particularly those of a certain age, will cite the Davson-Danielli model of the plasma membrane. However, the current authors would like to acknowledge Dr. Davson‘s enduring contributions in another area, that of his fundamental studies of the ocular and cerebrospinal fluids that form the basis of our current research in this important aspect of fluid electrolyte homeostasis in the brain.
- 12 April 2025
- Published by Springer Nature
- p. 85-99
Changes in the Blood Choroid Plexus Barrier in Response to Transient Receptor Potential, Vanilloid 4 Channel Activation
- 12 April 2025
- Published by Springer Nature
- p. 85-99
Changes in the Blood Choroid Plexus Barrier in Response to Transient Receptor Potential, Vanilloid 4 Channel Activation
- Open Access
- 17 April 2024
- Published by MDPI AG in Physiologia
- Vol. 4 (2) , 182-201
Understanding and Modeling the Pathophysiology of Hydrocephalus: In Search of Better Treatment Options
Hydrocephalus is caused by an overproduction of cerebrospinal fluid (CSF), an obstruction of fluid movement, or improper reabsorption. CSF accumulation in the brain’s ventricles causes ventriculomegaly, increased intracranial pressure, inflammation, and neural cell injury. Hydrocephalus can arise from brain trauma, hemorrhage, infection, tumors, or genetic mutations. Currently, there is no cure for hydrocephalus. Treatments like shunting and endoscopic third ventriculostomies are used, but, unfortunately, these therapeutic approaches require brain surgery and have high failure rates. The choroid plexus epithelium (CPe) is thought to be the major producer of CSF in the brain. It is a polarized epithelium that regulates ion and water movement from a fenestrated capillary exudate to the ventricles. Despite decades of research, control of electrolyte movement in the CPe is still not fully understood. This review discusses important transporters on the CPe, how some of these are regulated, and which of them could be potential targets for hydrocephalus treatment. To advance the development of hydrocephalus treatments, physiologically relevant preclinical models are crucial. This review covers some of the current animal and cell culture methods used to study hydrocephalus and highlights the need to develop standardized preclinical models that are used by multiple investigators in order to replicate critical findings and resolve controversies regarding potential drug targets.
- 17 April 2024
- Published by MDPI AG in Physiologia
- Vol. 4 (2) , 182-201
Open AccessUnderstanding and Modeling the Pathophysiology of Hydrocephalus: In Search of Better Treatment Options
Hydrocephalus is caused by an overproduction of cerebrospinal fluid (CSF), an obstruction of fluid movement, or improper reabsorption. CSF accumulation in the brain’s ventricles causes ventriculomegaly, increased intracranial pressure, inflammation, and neural cell injury. Hydrocephalus can arise from brain trauma, hemorrhage, infection, tumors, or genetic mutations. Currently, there is no cure for hydrocephalus. Treatments like shunting and endoscopic third ventriculostomies are used, but, unfortunately, these therapeutic approaches require brain surgery and have high failure rates. The choroid plexus epithelium (CPe) is thought to be the major producer of CSF in the brain. It is a polarized epithelium that regulates ion and water movement from a fenestrated capillary exudate to the ventricles. Despite decades of research, control of electrolyte movement in the CPe is still not fully understood. This review discusses important transporters on the CPe, how some of these are regulated, and which of them could be potential targets for hydrocephalus treatment. To advance the development of hydrocephalus treatments, physiologically relevant preclinical models are crucial. This review covers some of the current animal and cell culture methods used to study hydrocephalus and highlights the need to develop standardized preclinical models that are used by multiple investigators in order to replicate critical findings and resolve controversies regarding potential drug targets.